By Oliver Griffin

GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) on Wednesday reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.

The Trelegy Ellipta is approved by the U.S. Food and Drug Administration and designed to be used once daily for long-term maintenance treatment.

GlaxoSmithKline said the Trelegy Ellipta study, which involved 10,355 patients, showed significant reductions in the annual rate of on-treatment exacerbations when compared with the dual-therapy treatments it has in its portfolio.

Write to Oliver Griffin at oliver.griffin@dowjones.com

(END) Dow Jones Newswires

September 20, 2017 03:00 ET (07:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.